Literature DB >> 10577769

Growth factor therapy to the damaged inner ear: clinical prospects.

B Malgrange1, J M Rigo, T R Van de Water, H Staecker, G Moonen, P P Lefebvre.   

Abstract

Most hearing loss results from lesions of the sensory cells and/or of the neurons of the auditory part of the inner ear. There is currently no treatment able to stop the progression of a hearing loss or to restore a lost auditory function. In this paper, we review the progress which has been made with respect to the regeneration and the protection of the hair cells and of the auditory neurons in the cochlea. In particular, we emphasize the control by growth factors of the protection/repair mechanisms of the neurosensory structures within the inner ear, in the prospect of the possible clinical use of these molecules. Finally, we discuss the different approaches which can be used to deliver these therapeutic agents to the inner ear.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10577769     DOI: 10.1016/s0165-5876(99)00126-3

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  4 in total

1.  Stem cell transplantation for auditory nerve replacement.

Authors:  Richard A Altschuler; K Sue O'Shea; Josef M Miller
Journal:  Hear Res       Date:  2008-06-13       Impact factor: 3.208

2.  Inner ear drug delivery via a reciprocating perfusion system in the guinea pig.

Authors:  Zhiqiang Chen; Sharon G Kujawa; Michael J McKenna; Jason O Fiering; Mark J Mescher; Jeffrey T Borenstein; Erin E Leary Swan; William F Sewell
Journal:  J Control Release       Date:  2005-11-07       Impact factor: 9.776

3.  Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial.

Authors:  Takayuki Nakagawa; Tatsunori Sakamoto; Harukazu Hiraumi; Yayoi S Kikkawa; Norio Yamamoto; Kiyomi Hamaguchi; Kazuya Ono; Masaya Yamamoto; Yasuhiko Tabata; Satoshi Teramukai; Shiro Tanaka; Harue Tada; Rie Onodera; Atsushi Yonezawa; Ken-ichi Inui; Juichi Ito
Journal:  BMC Med       Date:  2010-11-25       Impact factor: 8.775

4.  A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment.

Authors:  Takayuki Nakagawa; Kozo Kumakawa; Shin-ichi Usami; Naohito Hato; Keiji Tabuchi; Mariko Takahashi; Keizo Fujiwara; Akira Sasaki; Shizuo Komune; Tatsunori Sakamoto; Harukazu Hiraumi; Norio Yamamoto; Shiro Tanaka; Harue Tada; Michio Yamamoto; Atsushi Yonezawa; Toshiko Ito-Ihara; Takafumi Ikeda; Akira Shimizu; Yasuhiko Tabata; Juichi Ito
Journal:  BMC Med       Date:  2014-11-19       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.